Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk-Reference-Cited by-同舟云学术

Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk

Published:2012-12-10 Issue:1 Volume:123 Page:329-334
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Staser Karl,Park Su-Jung,Rhodes Steven D.,Zeng Yi,He Yong Zheng,Shew Matthew A.,Gehlhausen Jeffrey R.,Cerabona Donna,Menon Keshav,Chen Shi,Sun Zejin,Yuan Jin,Ingram David A.,Nalepa Grzegorz,Yang Feng-Chun,Clapp D. Wade

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference19 articles.

1. Homozygous Inactivation of theNF1Gene in Bone Marrow Cells from Children with Neurofibromatosis Type 1 and Malignant Myeloid Disorders

2. Leukemic potential of doubly mutant Nf1 andWv hematopoietic cells

3. Nf1 Regulates Hematopoietic Progenitor Cell Growth and Ras Signaling in Response to Multiple Cytokines

4. Nf1 and Gmcsf Interact in Myeloid Leukemogenesis

5. β common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Screening and interventional strategies for the late effects and toxicities of hematological malignancy treatments in pediatric survivors;Expert Review of Hematology;2024-06-25

2. Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation;Frontiers in Oncology;2022-07-27

3. Molecular regulation of hematopoietic stem cell quiescence;Cellular and Molecular Life Sciences;2022-03-31

4. RAS and beyond: the many faces of the neurofibromatosis type 1 protein;Disease Models & Mechanisms;2022-02-01

5. MEK inhibition exerts temporal and myeloid cell-specific effects in the pathogenesis of neurofibromatosis type 1 arteriopathy;Scientific Reports;2021-12